Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Partners with NHLBI, BU to Find Cardiovascular Biomarkers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today announced a partnership to develop methods to measure potential biomarkers for atherosclerosis cardiovascular disease in plasma samples from the Framingham Heart Study.

The partnership brings together Sigma-Aldrich, Boston University, and the National Institutes of Health's National Heart, Lung, and Blood Institute.

NHLBI and BU's School of Medicine and School of Public Health run the Framingham study. NHLBI is providing funding to Sigma-Aldrich under a research sub-agreement with BU, though the amount of funding was not disclosed.

Under the five-year project, the three partners will analyze plasma samples from 7,000 participants in the Framingham study and investigate 180 potential biomarkers for CVD. Sigma-Aldrich anticipates developing antibody reagents for each identified target biomarker and to incorporate the reagents into a multiplexed, high-throughput platform to measure proteins of interest, it said in a statement.

"By embarking on this exciting effort, we believe we will help to develop the next generation of biomarker technologies for life science research and therapeutic applications, and provide greater understanding into the genetics and biological pathways of heart disease," Dave Smoller, president of Sigma-Aldrich's research biotech business unit, said in the company's statement.

The new project is part of a Framingham initiative called Systems Approach to Biomarker Research in Cardiovascular Disease for the identification and validation of new CVD biomarkers and eventually the development of new blood-based tests.

Last year, BG Medicine also entered into a collaboration with NHLBI and BU as part of the SABRe CVD initiative to analyze potential heart disease biomarkers in the hope of developing blood-based tests.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.